Modification of a Selective NTRK2 Agonist and Confirmation of Activity in a Glaucoma-on-a-Chip Model

CONCLUSION: The modified peptide studied herein showed improved stability over the original peptide (RNYK) and demonstrated potential for use as a BDNF agonist with neuroprotective properties for treatment of neurodegenerative disorders such as glaucoma.PMID:38638624 | PMC:PMC11022028 | DOI:10.18502/jovr.v19i1.15439

Source: Cell Research - April 19, 2024 Category: Cytology Authors: Fatemeh Nafian Shahin Yazdani Mohammad Javad Rasaee Babak Kamali Doust Azad Narsis Daftarian Mozhgan Rezaei Kanavi Source Type: research